PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20432929-8	2010	This Ang II-activated PI3-K/Akt cascade was significantly inhibited by valsartan, an AT1 receptor specific blocker (P<0.05), whereas enhanced by PD123319, an AT2 receptor antagonist (P<0.05).	Valsartan	71-80	angiogenin	Homo sapiens	5-8	
20104189-6	2010	RESULTS: The blood pressure response to Ang II was blocked by more than 90% with irbesartan alone or in association with HCTZ and with olmesartan/HCTZ and by nearly 60% with valsartan/HCTZ and losartan/HCTZ (P < 0.05).	Valsartan	174-183	angiogenin	Homo sapiens	40-43	
15977400-4	2000	The recent emergence of several specific Ang II-receptor antagonists such as losartan or valsartan has considerably widened the therapeutic options available for the treatment of hypertension-related diseases.	Valsartan	89-98	angiogenin	Homo sapiens	41-44	
24673471-9	2014	Pretreated with valsartan, cells were present with less autophagic, senescent, and apoptotic cells after Ang II stimulation.	Valsartan	16-25	angiogenin	Homo sapiens	105-108	
16097371-10	2005	Because we previously demonstrated that both the up-regulation of gp91phox and the acceleration of cellular senescence in Ang II-stimulated EPCs could be abolished by pre-treatment with the AT1R- specific antagonist, valsartan, we also explored the effect of estrogen on AT1R expression.	Valsartan	217-226	angiogenin	Homo sapiens	122-125	
11967720-10	2002	Multiple linear regression analysis showed that blockade of Ang II induced increase in blood pressure by valsartan contributed to only 30% of the total reduction in Ang II induced rise in PWV (R(2) = 0.306).	Valsartan	105-114	angiogenin	Homo sapiens	60-63